Heron Therapeutics, Inc. (HRTX)
USD 2.31
(-1.7%)
USD 2.31
(-1.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -103.79 Million USD | 38.33% |
| 2022 | -176.66 Million USD | 19.82% |
| 2021 | -215.25 Million USD | 4.53% |
| 2020 | -222.53 Million USD | -9.35% |
| 2019 | -201.23 Million USD | -13.44% |
| 2018 | -174.65 Million USD | 4.21% |
| 2017 | -192.01 Million USD | -12.35% |
| 2016 | -169.38 Million USD | -76.34% |
| 2015 | -96.19 Million USD | -29.99% |
| 2014 | -73.98 Million USD | -36.92% |
| 2013 | -54.45 Million USD | -128.51% |
| 2012 | -23.83 Million USD | -118.97% |
| 2011 | -10.88 Million USD | 12.57% |
| 2010 | -6.96 Million USD | -25.97% |
| 2009 | -9.86 Million USD | 56.98% |
| 2008 | -22.51 Million USD | 11.16% |
| 2007 | -19.44 Million USD | 38.8% |
| 2006 | 5.91 Million USD | -426.01% |
| 2005 | -8.02 Million USD | 11.02% |
| 2004 | -9.02 Million USD | -43.12% |
| 2003 | -5.95 Million USD | -42.97% |
| 2002 | -4.58 Million USD | 30.91% |
| 2001 | -6.76 Million USD | -43.44% |
| 2000 | -4.03 Million USD | -239.06% |
| 1999 | -1.5 Million USD | -13.51% |
| 1998 | -2 Million USD | 311.11% |
| 1997 | -800 Thousand USD | 120.0% |
| 1996 | -7.1 Million USD | 37.5% |
| 1995 | -7.4 Million USD | 5.26% |
| 1994 | -7.9 Million USD | 24.75% |
| 1993 | -9.2 Million USD | -65.57% |
| 1992 | -5.3 Million USD | -69.44% |
| 1991 | -3.2 Million USD | 17.95% |
| 1990 | -3.9 Million USD | 15.22% |
| 1989 | -4.6 Million USD | 8.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.1 Million USD | 47.6% |
| 2024 Q2 | -5.8 Million USD | -41.25% |
| 2023 Q3 | -24.2 Million USD | 41.91% |
| 2023 Q4 | -9.5 Million USD | 60.73% |
| 2023 Q2 | -41.66 Million USD | -28.81% |
| 2023 FY | - USD | 38.33% |
| 2023 Q1 | -32.34 Million USD | -58.9% |
| 2022 FY | - USD | 19.82% |
| 2022 Q1 | -62.2 Million USD | -16.19% |
| 2022 Q2 | -48.82 Million USD | 21.5% |
| 2022 Q3 | -41.17 Million USD | 15.67% |
| 2022 Q4 | -20.35 Million USD | 50.57% |
| 2021 Q2 | -59.73 Million USD | -16.27% |
| 2021 Q1 | -51.37 Million USD | 16.19% |
| 2021 Q3 | -50.95 Million USD | 14.7% |
| 2021 Q4 | -53.53 Million USD | -5.07% |
| 2021 FY | - USD | 4.53% |
| 2020 Q4 | -61.29 Million USD | -6.39% |
| 2020 Q3 | -57.61 Million USD | -4.75% |
| 2020 FY | - USD | -9.35% |
| 2020 Q1 | -52.11 Million USD | 12.21% |
| 2020 Q2 | -55 Million USD | -5.55% |
| 2019 Q3 | -34.33 Million USD | 33.06% |
| 2019 Q2 | -51.28 Million USD | 20.15% |
| 2019 Q1 | -64.23 Million USD | -25.18% |
| 2019 FY | - USD | -13.44% |
| 2019 Q4 | -59.36 Million USD | -72.91% |
| 2018 Q4 | -51.31 Million USD | -23.95% |
| 2018 Q2 | -38.52 Million USD | 25.36% |
| 2018 FY | - USD | 4.21% |
| 2018 Q1 | -51.6 Million USD | 14.69% |
| 2018 Q3 | -41.39 Million USD | -7.46% |
| 2017 Q4 | -60.49 Million USD | -47.87% |
| 2017 Q1 | -48.97 Million USD | -4.63% |
| 2017 Q2 | -41.64 Million USD | 14.96% |
| 2017 FY | - USD | -12.35% |
| 2017 Q3 | -40.9 Million USD | 1.76% |
| 2016 Q3 | -47.43 Million USD | -10.78% |
| 2016 FY | - USD | -76.34% |
| 2016 Q1 | -33.07 Million USD | -6.48% |
| 2016 Q4 | -46.8 Million USD | 1.32% |
| 2016 Q2 | -42.81 Million USD | -29.45% |
| 2015 Q4 | -31.06 Million USD | -39.18% |
| 2015 FY | - USD | -29.99% |
| 2015 Q2 | -22.84 Million USD | -13.04% |
| 2015 Q1 | -20.2 Million USD | -3.66% |
| 2015 Q3 | -22.31 Million USD | 2.31% |
| 2014 FY | - USD | -36.92% |
| 2014 Q4 | -19.49 Million USD | -3.68% |
| 2014 Q3 | -18.8 Million USD | -0.73% |
| 2014 Q2 | -18.66 Million USD | -8.47% |
| 2014 Q1 | -17.2 Million USD | -24.41% |
| 2013 FY | - USD | -128.51% |
| 2013 Q1 | -12.68 Million USD | -46.99% |
| 2013 Q4 | -13.83 Million USD | -9.99% |
| 2013 Q2 | -15.13 Million USD | -19.3% |
| 2013 Q3 | -12.57 Million USD | 16.88% |
| 2012 Q4 | -8.62 Million USD | -43.78% |
| 2012 FY | - USD | -118.97% |
| 2012 Q3 | -6 Million USD | -37.01% |
| 2012 Q2 | -4.38 Million USD | 7.16% |
| 2012 Q1 | -4.71 Million USD | -15.75% |
| 2011 Q1 | -1.26 Million USD | 34.15% |
| 2011 Q4 | -4.07 Million USD | -0.74% |
| 2011 Q2 | -1.49 Million USD | -17.92% |
| 2011 Q3 | -4.04 Million USD | -170.82% |
| 2011 FY | - USD | 12.57% |
| 2010 Q1 | -5.3 Million USD | -164.14% |
| 2010 Q2 | -3.63 Million USD | 31.39% |
| 2010 Q3 | -1.58 Million USD | 56.58% |
| 2010 Q4 | -1.92 Million USD | -21.77% |
| 2010 FY | - USD | -25.97% |
| 2009 Q1 | -2.87 Million USD | 21.35% |
| 2009 Q3 | -1.12 Million USD | 70.95% |
| 2009 Q4 | -2 Million USD | -78.49% |
| 2009 FY | - USD | 56.98% |
| 2009 Q2 | -3.87 Million USD | -34.76% |
| 2008 Q4 | -3.65 Million USD | 40.8% |
| 2008 Q1 | -6.99 Million USD | 9.59% |
| 2008 Q2 | -6.14 Million USD | 12.09% |
| 2008 FY | - USD | 11.16% |
| 2008 Q3 | -6.17 Million USD | -0.41% |
| 2007 Q2 | -6.52 Million USD | -7.42% |
| 2007 Q1 | -6.07 Million USD | -6.15% |
| 2007 Q3 | -5.23 Million USD | 19.84% |
| 2007 FY | - USD | 38.8% |
| 2007 Q4 | -7.73 Million USD | -47.79% |
| 2006 Q3 | -3.81 Million USD | 18.7% |
| 2006 Q1 | -27.73 Million USD | -1066.81% |
| 2006 FY | - USD | -426.01% |
| 2006 Q2 | -4.68 Million USD | 83.09% |
| 2006 Q4 | -5.72 Million USD | -50.18% |
| 2005 Q2 | -2.58 Million USD | -114.42% |
| 2005 Q4 | -2.37 Million USD | -29.47% |
| 2005 Q3 | -1.83 Million USD | 29.06% |
| 2005 FY | - USD | 11.02% |
| 2005 Q1 | -1.2 Million USD | 47.66% |
| 2004 FY | - USD | -43.12% |
| 2004 Q1 | -2.52 Million USD | -75.19% |
| 2004 Q4 | -2.3 Million USD | -26.7% |
| 2004 Q3 | -1.82 Million USD | 23.24% |
| 2004 Q2 | -2.37 Million USD | 6.21% |
| 2003 FY | - USD | -42.97% |
| 2003 Q3 | -1.08 Million USD | 31.81% |
| 2003 Q4 | -1.44 Million USD | -15.44% |
| 2003 Q2 | -1.84 Million USD | -3.04% |
| 2003 Q1 | -1.78 Million USD | -511.34% |
| 2002 Q3 | -1.43 Million USD | 10.33% |
| 2002 FY | - USD | 30.91% |
| 2002 Q4 | -293 Thousand USD | 80.51% |
| 2002 Q1 | -1.22 Million USD | 37.2% |
| 2002 Q2 | -1.66 Million USD | -35.54% |
| 2001 Q4 | -1.95 Million USD | -1.88% |
| 2001 FY | - USD | -43.44% |
| 2001 Q1 | -1.31 Million USD | 25.86% |
| 2001 Q2 | -1.59 Million USD | -21.3% |
| 2001 Q3 | -1.91 Million USD | -20.25% |
| 2000 FY | - USD | -239.06% |
| 2000 Q3 | -890 Thousand USD | 12.57% |
| 2000 Q2 | -1.01 Million USD | -337.56% |
| 2000 Q4 | -1.77 Million USD | -99.5% |
| 2000 Q1 | -716.05 Thousand USD | -116.62% |
| 1999 Q1 | 700 Thousand USD | -61.11% |
| 1999 FY | - USD | -13.51% |
| 1999 Q3 | -679.52 Thousand USD | 16.67% |
| 1999 Q2 | 600 Thousand USD | -14.29% |
| 1999 Q4 | 1.4 Million USD | 100.0% |
| 1998 Q1 | 600 Thousand USD | 100.0% |
| 1998 FY | - USD | 311.11% |
| 1998 Q2 | 700 Thousand USD | 0.0% |
| 1998 Q4 | 1.8 Million USD | 100.0% |
| 1998 Q3 | 700 Thousand USD | 50.0% |
| 1997 FY | - USD | 120.0% |
| 1997 Q2 | -200 Thousand USD | -125.0% |
| 1997 Q4 | 400 Thousand USD | 250.0% |
| 1997 Q3 | -100 Thousand USD | 0.0% |
| 1997 Q1 | 900 Thousand USD | 900.0% |
| 1996 FY | - USD | 37.5% |
| 1996 Q1 | -1.3 Million USD | 45.83% |
| 1996 Q3 | -1.5 Million USD | -6.67% |
| 1996 Q2 | -1.4 Million USD | -15.38% |
| 1996 Q4 | -1.4 Million USD | 93.75% |
| 1995 Q2 | -1.7 Million USD | -157.14% |
| 1995 Q4 | -3.1 Million USD | -14.29% |
| 1995 Q3 | -1.8 Million USD | -16.67% |
| 1995 FY | - USD | 5.26% |
| 1995 Q1 | -600 Thousand USD | 12.5% |
| 1994 Q2 | -2.5 Million USD | -52.94% |
| 1994 Q1 | -1.6 Million USD | 34.62% |
| 1994 FY | - USD | 24.75% |
| 1994 Q3 | -2.7 Million USD | -7.69% |
| 1994 Q4 | -1.4 Million USD | 71.43% |
| 1993 Q3 | -2.4 Million USD | 7.14% |
| 1993 FY | - USD | -65.57% |
| 1993 Q4 | -2.5 Million USD | 0.0% |
| 1993 Q1 | -1.9 Million USD | -4.55% |
| 1993 Q2 | -2.6 Million USD | -21.74% |
| 1992 Q1 | -1.9 Million USD | -66.67% |
| 1992 FY | - USD | -69.44% |
| 1992 Q3 | -700 Thousand USD | 10.0% |
| 1992 Q4 | -1.9 Million USD | -144.44% |
| 1992 Q2 | -800 Thousand USD | 50.0% |
| 1991 FY | - USD | 26.53% |
| 1991 Q4 | -1.1 Million USD | -9.09% |
| 1991 Q1 | -1 Million USD | 31.25% |
| 1991 Q2 | -200 Thousand USD | 72.73% |
| 1991 Q3 | -1 Million USD | -266.67% |
| 1990 FY | - USD | 10.91% |
| 1990 Q1 | -800 Thousand USD | 23.08% |
| 1990 Q3 | -1.1 Million USD | -20.0% |
| 1990 Q4 | -1 Million USD | -33.33% |
| 1990 Q2 | -900 Thousand USD | 0.0% |
| 1989 Q1 | 500 Thousand USD | 106.33% |
| 1989 Q3 | -900 Thousand USD | 15.38% |
| 1989 Q4 | -1.1 Million USD | -18.18% |
| 1989 FY | - USD | 9.84% |
| 1989 Q2 | -1 Million USD | -360.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Absci Corporation | -95.45 Million USD | -8.732% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 45.163% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 59.808% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -949.793% |
| Apollomics, Inc. | -171.74 Million USD | 39.567% |
| 180 Life Sciences Corp. | -22.13 Million USD | -368.925% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -231.033% |
| Bicycle Therapeutics plc | -183.4 Million USD | 43.407% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | -38.732% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 37.256% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -381.879% |
| Chimerix, Inc. | -92.97 Million USD | -11.636% |
| CRISPR Therapeutics AG | -202.7 Million USD | 48.796% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 540.3% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | -50.421% |
| Fortress Biotech, Inc. | -133.64 Million USD | 22.336% |
| Fortress Biotech, Inc. | -133.64 Million USD | 22.336% |
| Gritstone bio, Inc. | -126.86 Million USD | 18.186% |
| Allakos Inc. | -189.91 Million USD | 45.348% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -114.106% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 11.779% |
| Cytokinetics, Incorporated | -456.68 Million USD | 77.273% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | -9.518% |
| Innoviva, Inc. | 248.96 Million USD | 141.69% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -67671.908% |
| NLS Pharmaceutics AG | -11.79 Million USD | -779.917% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 17.525% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -805432.682% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | -1.492% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | -17.323% |
| ImmuCell Corporation | -2.5 Million USD | -4044.92% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 20.418% |
| Incyte Corporation | 919.42 Million USD | 111.289% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 20.399% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -1524.638% |
| Mustang Bio, Inc. | -48.06 Million USD | -115.95% |
| MiMedx Group, Inc. | 40.51 Million USD | 356.169% |
| MEI Pharma, Inc. | 26.38 Million USD | 493.45% |
| MacroGenics, Inc. | 2.01 Million USD | 5245.86% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 24291.74% |
| Mereo BioPharma Group plc | -26.05 Million USD | -298.342% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -780.17% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 17.295% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 114.569% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -378.493% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -553.602% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -876.131% |
| NextCure, Inc. | -59.03 Million USD | -75.802% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -102.644% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -941.252% |
| Onconetix, Inc. | -36.7 Million USD | -182.76% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 4743.937% |
| Opthea Limited | -200.01 Million USD | 48.109% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -76.778% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -3672.087% |
| PDS Biotechnology Corporation | -40.08 Million USD | -158.93% |
| Precigen, Inc. | -89.22 Million USD | -16.325% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -355.988% |
| Prime Medicine, Inc. | -193.75 Million USD | 46.432% |
| PureTech Health plc | -11.62 Million USD | -792.681% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 56.136% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 102.23% |
| Replimune Group, Inc. | -230.19 Million USD | 54.912% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -108916.049% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -511.224% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -477.474% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 75.895% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -330.46% |
| Sesen Bio, Inc. | -50.84 Million USD | -104.154% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -18.718% |
| Solid Biosciences Inc. | -93.43 Million USD | -11.086% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 54.862% |
| SciSparc Ltd. | -5.28 Million USD | -1865.013% |
| Sutro Biopharma, Inc. | -67.91 Million USD | -52.826% |
| TG Therapeutics, Inc. | 26.1 Million USD | 497.67% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 9.025% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -1348.597% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 68.186% |
| UroGen Pharma Ltd. | -63.83 Million USD | -62.604% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -66.876% |
| XOMA Corporation | -39.36 Million USD | -163.686% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 62.326% |
| AbCellera Biologics Inc. | -192.15 Million USD | 45.986% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -82.881% |
| Cassava Sciences, Inc. | -95.68 Million USD | -8.47% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -133.573% |
| Precision BioSciences, Inc. | -32.04 Million USD | -223.925% |
| Dyadic International, Inc. | -8.22 Million USD | -1161.182% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -929.07% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -35567.354% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -254.747% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 15.276% |
| IGM Biosciences, Inc. | -253.35 Million USD | 59.033% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 3.091% |
| Acelyrin, Inc. | -381.52 Million USD | 72.796% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -105.236% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 202.03% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -421.243% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -329.496% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 33.972% |
| Senti Biosciences, Inc. | -61.33 Million USD | -69.219% |
| Mesoblast Limited | -61.33 Million USD | -69.233% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 27.52% |
| ChromaDex Corporation | -3.89 Million USD | -2565.434% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2066.185% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -1411.241% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 42084.338% |
| Seer, Inc. | -97.88 Million USD | -6.035% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -337.295% |
| Novavax, Inc. | -487.39 Million USD | 78.705% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -4513.554% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 39.736% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -99.034% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 53.921% |
| Celcuity Inc. | -58.3 Million USD | -78.0% |
| ContextLogic Inc. | -324 Million USD | 67.965% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 34.742% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | -34.197% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 107.161% |
| Amarin Corporation plc | -50.9 Million USD | -103.907% |
| AnaptysBio, Inc. | -143.16 Million USD | 27.501% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -266.614% |
| Aptorum Group Limited | -9.59 Million USD | -981.28% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 55.845% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 40.917% |
| Ardelyx, Inc. | -55.35 Million USD | -87.506% |
| Celularity Inc. | -183.94 Million USD | 43.575% |
| Omeros Corporation | -163.61 Million USD | 36.561% |
| Humacyte, Inc. | -96.45 Million USD | -7.603% |
| Immunocore Holdings plc | -59.64 Million USD | -74.005% |
| IO Biotech, Inc. | -91.22 Million USD | -13.772% |
| GT Biopharma, Inc. | 5.97 Million USD | 1835.942% |
| Cabaletta Bio, Inc. | -73.23 Million USD | -41.727% |
| Summit Therapeutics Inc. | 1 Million USD | 10468.831% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -235.853% |
| Pulmatrix, Inc. | -12.64 Million USD | -720.75% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 79.501% |
| Evogene Ltd. | -23.2 Million USD | -347.302% |
| CorMedix Inc. | -48.88 Million USD | -112.31% |
| BioLineRx Ltd. | -57.06 Million USD | -81.897% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -219.823% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -237.645% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 68.58% |
| scPharmaceuticals Inc. | -46.06 Million USD | -125.336% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 4.332% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 195.816% |
| NLS Pharmaceutics AG | -11.79 Million USD | -779.917% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -330.46% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 30.168% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -660.214% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -306.724% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 7.579% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | -26.217% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -80.898% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -482.784% |
| Daré Bioscience, Inc. | -30.7 Million USD | -238.068% |
| bluebird bio, Inc. | -167.16 Million USD | 37.909% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 133.451% |
| DBV Technologies S.A. | -85.98 Million USD | -20.714% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 55.549% |
| Galecto, Inc. | -37.51 Million USD | -176.639% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -210.885% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -119.128% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 49.784% |
| GlycoMimetics, Inc. | -39.12 Million USD | -165.303% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 54.364% |
| ADMA Biologics, Inc. | 5.12 Million USD | 2127.188% |
| Clene Inc. | -43.24 Million USD | -140.031% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 65.353% |
| Aptose Biosciences Inc. | -52.26 Million USD | -98.577% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 3.667% |
| Soligenix, Inc. | -7.85 Million USD | -1221.711% |
| Century Therapeutics, Inc. | -121.2 Million USD | 14.369% |
| Kura Oncology, Inc. | -164.95 Million USD | 37.079% |
| Surrozen, Inc. | -41.13 Million USD | -152.345% |
| TScan Therapeutics, Inc. | -80.09 Million USD | -29.581% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -10737.191% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -2308.726% |
| Autolus Therapeutics plc | -156.77 Million USD | 33.793% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -22.603% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -420.678% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 7.768% |
| GRI Bio, Inc. | -10.89 Million USD | -852.395% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -2198.462% |
| Janux Therapeutics, Inc. | -71.02 Million USD | -46.137% |
| INmune Bio, Inc. | - USD | Infinity% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -172.183% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -577.011% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -1161.699% |
| Jaguar Health, Inc. | -33.13 Million USD | -213.278% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -559.28% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -82.588% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -350.134% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 60.98% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 46.482% |
| Verastem, Inc. | -83.16 Million USD | -24.801% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 34.404% |
| Histogen Inc. | -10.5 Million USD | -888.213% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -626.85% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | -53.025% |
| Surrozen, Inc. | -41.13 Million USD | -152.345% |
| Organovo Holdings, Inc. | -14.8 Million USD | -601.013% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 3236520.331% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -1144.806% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 37.5% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -110.709% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -589.417% |
| Kronos Bio, Inc. | -121.83 Million USD | 14.806% |
| Turnstone Biologics Corp. | -56.23 Million USD | -84.572% |
| Synaptogenix, Inc. | -8.3 Million USD | -1149.376% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -576.654% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -32233.956% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | -64.626% |
| Exelixis, Inc. | 196.6 Million USD | 152.793% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 26.602% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 79.041% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -59.717% |
| ESSA Pharma Inc. | -26.45 Million USD | -292.33% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -2494.835% |
| Avid Bioservices, Inc. | -11.48 Million USD | -804.033% |
| Insmed Incorporated | -654.73 Million USD | 84.148% |
| MediWound Ltd. | -4.89 Million USD | -2021.234% |
| OmniAb, Inc. | -49.73 Million USD | -108.707% |
| Alector, Inc. | -142.89 Million USD | 27.363% |
| Seres Therapeutics, Inc. | -85.43 Million USD | -21.488% |
| Zai Lab Limited | -366.57 Million USD | 71.686% |
| AlloVir, Inc. | -190.14 Million USD | 45.415% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 64.288% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 5.427% |
| Aura Biosciences, Inc. | -83.69 Million USD | -24.011% |
| Immunic, Inc. | -99.11 Million USD | -4.722% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 21.173% |
| Veracyte, Inc. | -49.4 Million USD | -110.067% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -1369.324% |
| FibroGen, Inc. | -261.4 Million USD | 60.295% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -831.622% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 219.56% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -1382.462% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -454.537% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -308.276% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 360.196% |
| Fortrea Holdings Inc. | 167.3 Million USD | 162.039% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 22.705% |
| XBiotech Inc. | -35.76 Million USD | -190.197% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -59.717% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 31.795% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 19720.416% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | -59.068% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 0.635% |
| Agenus Inc. | -145.92 Million USD | 28.873% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -304.3% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -153.975% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 79.903% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -85.273% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 10.782% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -368.174% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 14.996% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -1778.402% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -308.759% |
| Lantern Pharma Inc. | -15.78 Million USD | -557.465% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| Ainos, Inc. | -8.77 Million USD | -1083.071% |
| Pluri Inc. | -20.22 Million USD | -413.187% |
| Prothena Corporation plc | -190.1 Million USD | 45.404% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 19.038% |
| Rallybio Corporation | -72.37 Million USD | -43.413% |
| Kodiak Sciences Inc. | -259.02 Million USD | 59.929% |
| Cue Biopharma, Inc. | -46.05 Million USD | -125.38% |
| MeiraGTx Holdings plc | -57.05 Million USD | -81.925% |
| Annexon, Inc. | -141.57 Million USD | 26.688% |
| Assembly Biosciences, Inc. | -64.19 Million USD | -61.68% |
| Moderna, Inc. | -3.28 Billion USD | 96.839% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -435.784% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -325.988% |
| Blueprint Medicines Corporation | -474.61 Million USD | 78.131% |
| Immix Biopharma, Inc. | -16.13 Million USD | -543.247% |
| CalciMedica, Inc. | -34.18 Million USD | -203.583% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 24.289% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 38.384% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -76.547% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 58.876% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -214.846% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | -2.546% |
| Nutriband Inc. | -5.12 Million USD | -1926.484% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -139.859% |
| Vor Biopharma Inc. | -114.37 Million USD | 9.25% |
| Roivant Sciences Ltd. | -996.51 Million USD | 89.585% |
| Alkermes plc | 495.04 Million USD | 120.966% |
| ProKidney Corp. | -147.66 Million USD | 29.713% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -60.831% |
| Arcellx, Inc. | -64.14 Million USD | -61.808% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 81.645% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 7.128% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -51282.178% |
| Atai Life Sciences N.V. | -36.31 Million USD | -185.842% |
| Renovaro Biosciences Inc. | -79.51 Million USD | -30.528% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | -27.645% |
| MediciNova, Inc. | -9.87 Million USD | -950.53% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 17.587% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -6682.9% |
| GeoVax Labs, Inc. | -26.66 Million USD | -289.189% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 53.868% |
| Biomea Fusion, Inc. | -124.62 Million USD | 16.713% |
| RenovoRx, Inc. | -11.39 Million USD | -811.255% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 45.47% |
| Geron Corporation | -174.78 Million USD | 40.616% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -245.685% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 3.105% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 55.545% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -354.133% |
| Royalty Pharma plc | 1.88 Billion USD | 105.5% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 50.061% |
| Imunon, Inc. | -19.87 Million USD | -422.138% |
| BioAtla, Inc. | -122.24 Million USD | 15.092% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 65.436% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -150.421% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 37.505% |
| Structure Therapeutics Inc. | -102.45 Million USD | -1.301% |
| 89bio, Inc. | -134.46 Million USD | 22.81% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | -4.572% |
| aTyr Pharma, Inc. | -52.17 Million USD | -98.919% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | -23.835% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 55.751% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -1190.576% |
| Akari Therapeutics, Plc | -16.8 Million USD | -517.736% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 55101.961% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 122.966% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 36.505% |
| Liquidia Corporation | -70.05 Million USD | -48.166% |
| Entera Bio Ltd. | -8.8 Million USD | -1078.919% |
| GH Research PLC | -41.15 Million USD | -152.21% |
| Vericel Corporation | 2.86 Million USD | 3724.022% |
| Arbutus Biopharma Corporation | -70.98 Million USD | -46.215% |
| Xencor, Inc. | -125.87 Million USD | 17.543% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -7175.761% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -577.011% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -414.902% |
| Vaxcyte, Inc. | -464.88 Million USD | 77.674% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 50.696% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -848.565% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -1524.638% |
| Portage Biotech Inc. | -18.19 Million USD | -470.317% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -6682.9% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 0.757% |
| OncoCyte Corporation | -23.12 Million USD | -348.869% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -818.484% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -805.939% |
| Purple Biotech Ltd. | -22.22 Million USD | -367.006% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -260.689% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -258.361% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 38.389% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -1519.22% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -251.79% |
| United Therapeutics Corporation | 1.38 Billion USD | 107.484% |
| HilleVax, Inc. | -132.46 Million USD | 21.646% |
| Silo Pharma, Inc. | -3.62 Million USD | -2762.269% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -1596.905% |
| Pharming Group N.V. | 9.87 Million USD | 1150.845% |
| Tharimmune, Inc. | -9.3 Million USD | -1015.732% |
| Genprex, Inc. | -31.06 Million USD | -234.16% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -23.584% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 44.652% |
| Pyxis Oncology, Inc. | -78.49 Million USD | -32.231% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -13485.34% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 68880.152% |
| OKYO Pharma Limited | -15.74 Thousand USD | -659069.674% |
| Savara Inc. | -59.13 Million USD | -75.523% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -414.867% |
| Curis, Inc. | -45.13 Million USD | -129.939% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -583.24% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -288.24% |
| BeiGene, Ltd. | -1.12 Billion USD | 90.771% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | -14.89% |
| Erasca, Inc. | -121.31 Million USD | 14.441% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -2207.127% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -2207.127% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -143.592% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -1737.677% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -73.414% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 25.348% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 49.581% |
| Adicet Bio, Inc. | -136.53 Million USD | 23.981% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -12.721% |
| Aditxt, Inc. | -25.45 Million USD | -307.7% |
| Adagene Inc. | -14.95 Million USD | -594.224% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1319.844% |
| Quantum-Si incorporated | -91.8 Million USD | -13.058% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 182.078% |
| Compugen Ltd. | -12.51 Million USD | -729.275% |
| Generation Bio Co. | -133.3 Million USD | 22.137% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -25.005% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | -20.656% |
| Invivyd, Inc. | -196.61 Million USD | 47.211% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 72.259% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -1019.076% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 482.235% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -909.159% |
| 2seventy bio, Inc. | -206.41 Million USD | 49.718% |
| Instil Bio, Inc. | -146.12 Million USD | 28.969% |
| Capricor Therapeutics, Inc. | -23 Million USD | -351.094% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -2330.531% |
| GeoVax Labs, Inc. | -26.66 Million USD | -289.189% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -182.586% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 2213.78% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 34.476% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 84.832% |
| Evaxion Biotech A/S | -21.4 Million USD | -384.941% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | -56.278% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 52.317% |
| Tyra Biosciences, Inc. | -79.59 Million USD | -30.405% |
| Cingulate Inc. | -22.95 Million USD | -352.213% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -1291.127% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -178.39% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -77.811% |
| Clearmind Medicine Inc. | -8.71 Million USD | -1091.551% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | -39.614% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -4151.307% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -2.941% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 72.684% |
| ImmunityBio, Inc. | -436.18 Million USD | 76.204% |
| Korro Bio, Inc. | -80.9 Million USD | -28.29% |
| Kineta, Inc. | -15.71 Million USD | -560.507% |
| BioVie Inc. | -31.95 Million USD | -224.855% |
| Codexis, Inc. | -49.28 Million USD | -110.604% |
| Celularity Inc. | -183.94 Million USD | 43.575% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -564.779% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 53.143% |
| Virax Biolabs Group Limited | -6.6 Million USD | -1470.43% |
| Cibus, Inc. | -314.58 Million USD | 67.007% |
| IN8bio, Inc. | -28.5 Million USD | -264.131% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 7.822% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -271.282% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 54.875% |
| Eyenovia, Inc. | -24.1 Million USD | -330.564% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 331.761% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -31934.568% |
| Elevation Oncology, Inc. | -41.46 Million USD | -150.3% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | -40.632% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -130.577% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 15.942% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -236.092% |
| Moolec Science SA | -52.07 Million USD | -99.31% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -101.124% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -156.803% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 13.212% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -114.123% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1013.14% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -400.425% |
| Humacyte, Inc. | -96.45 Million USD | -7.603% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | -31.59% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 2661.5% |
| Genelux Corporation | -24.16 Million USD | -329.514% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -207.077% |
| Notable Labs, Ltd. | -14.4 Million USD | -620.778% |
| Immunovant, Inc. | -269.97 Million USD | 61.555% |
| Quantum-Si incorporated | -91.8 Million USD | -13.058% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -437.56% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -1.745% |
| Acasti Pharma Inc. | -11.3 Million USD | -818.432% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -366.413% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -180.292% |
| PepGen Inc. | -83.58 Million USD | -24.18% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -353.3% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -2075.141% |
| Immuneering Corporation | -58.06 Million USD | -78.764% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 3236520.331% |
| Belite Bio, Inc | -31.52 Million USD | -229.195% |
| XOMA Corporation | -39.36 Million USD | -163.686% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | -53.887% |
| Bionomics Limited | -9.83 Million USD | -955.119% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -199.925% |
| uniQure N.V. | -253.1 Million USD | 58.992% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1319.844% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 19.854% |
| Forte Biosciences, Inc. | -32.47 Million USD | -219.586% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -1189.266% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -267.809% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -31934.568% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -831.622% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -552.739% |
| Altimmune, Inc. | -87.93 Million USD | -18.033% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 15.094% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -199.925% |
| Peak Bio, Inc. | -1356.23 USD | -7652879.214% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -113.573% |
| Benitec Biopharma Inc. | -22.49 Million USD | -361.503% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 57.164% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -263.634% |
| Zura Bio Limited | -60.56 Million USD | -71.379% |
| PolyPid Ltd. | -20.26 Million USD | -412.224% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -263.634% |
| argenx SE | -216.02 Million USD | 51.953% |
| Immunome, Inc. | -28.27 Million USD | -267.132% |
| Verona Pharma plc | -52.46 Million USD | -97.821% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | -9.518% |
| Shattuck Labs, Inc. | -87.61 Million USD | -18.464% |
| CervoMed Inc. | -2.17 Million USD | -4678.914% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -717.711% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -115.452% |
| Moolec Science SA | -52.07 Million USD | -99.31% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -505.555% |
| Design Therapeutics, Inc. | -66.32 Million USD | -56.49% |
| Leap Therapeutics, Inc. | -80.98 Million USD | -28.159% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -174.946% |
| Achilles Therapeutics plc | -70.44 Million USD | -47.344% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -4151.307% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -87.242% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -105.325% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | -59.002% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -91.817% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -128.738% |
| Beam Therapeutics Inc. | -156.47 Million USD | 33.668% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 23.956% |
| AEON Biopharma, Inc. | -48.36 Million USD | -114.619% |
| Aadi Bioscience, Inc. | -65.36 Million USD | -58.788% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | -26.681% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -740.419% |
| NeurAxis, Inc. | -6.66 Million USD | -1457.387% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 75.717% |
| Lumos Pharma, Inc. | -36.57 Million USD | -183.817% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 1880.539% |
| Palisade Bio, Inc. | -12.28 Million USD | -745.143% |
| Nutriband Inc. | -5.12 Million USD | -1926.484% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 1.336% |
| Neurogene Inc. | -52.28 Million USD | -98.508% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -1136.208% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | -11.583% |
| Athira Pharma, Inc. | -116.7 Million USD | 11.063% |
| HCW Biologics Inc. | -23.57 Million USD | -340.243% |
| XOMA Corporation | -39.36 Million USD | -163.686% |
| Nektar Therapeutics | -243.1 Million USD | 57.306% |
| Arvinas, Inc. | -394.8 Million USD | 73.71% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 55101.961% |
| Merus N.V. | -149.2 Million USD | 30.438% |
| Omega Therapeutics, Inc. | -93.49 Million USD | -11.019% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -232.028% |
| Rezolute, Inc. | -68.42 Million USD | -51.692% |
| Clene Inc. | -43.24 Million USD | -140.031% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -573.004% |
| BeyondSpring Inc. | -21.54 Million USD | -381.857% |
| Synlogic, Inc. | -55.16 Million USD | -88.162% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -758.992% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -875.305% |
| Peak Bio, Inc. | -1356.23 USD | -7652879.214% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -219.704% |
| Krystal Biotech, Inc. | 17.9 Million USD | 679.714% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 12.355% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 69.593% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -2153.197% |
| MannKind Corporation | 15.12 Million USD | 786.047% |
| Ikena Oncology, Inc. | -74.39 Million USD | -39.511% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -724.204% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 610.612% |
| Gossamer Bio, Inc. | -172.15 Million USD | 39.709% |
| CohBar, Inc. | -12.06 Million USD | -760.219% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -306.884% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -245.685% |
| Legend Biotech Corporation | -477.87 Million USD | 78.28% |
| Mural Oncology plc | -192.72 Million USD | 46.144% |
| Disc Medicine, Inc. | -91.02 Million USD | -14.026% |
| Champions Oncology, Inc. | -5.05 Million USD | -1953.66% |
| REGENXBIO Inc. | -239.46 Million USD | 56.657% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -868.373% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -86.154% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -167.724% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 7.991% |
| Vaxart, Inc. | -74.72 Million USD | -38.902% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -194.794% |
| Cellectis S.A. | -98.09 Million USD | -5.808% |
| Longeveron Inc. | -20.06 Million USD | -417.408% |
| Repare Therapeutics Inc. | -114.27 Million USD | 9.172% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 76.368% |
| Inozyme Pharma, Inc. | -74.81 Million USD | -38.737% |
| Revolution Medicines, Inc. | -430.58 Million USD | 75.895% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -1550.374% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -237.107% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -39.15% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 2216.908% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -846.575% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 102.254% |
| Denali Therapeutics Inc. | -179.97 Million USD | 42.329% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -108916.049% |
| Veru Inc. | -89.97 Million USD | -15.356% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -286.16% |
| Cingulate Inc. | -22.95 Million USD | -352.213% |
| Passage Bio, Inc. | -98.34 Million USD | -5.543% |
| Context Therapeutics Inc. | -25.06 Million USD | -314.165% |
| Exicure, Inc. | -15.53 Million USD | -567.945% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 49.631% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -180.701% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -1640.718% |
| Nuvalent, Inc. | -149.49 Million USD | 30.57% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -1176.275% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | -20.837% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -243.933% |
| OmniAb, Inc. | -49.73 Million USD | -108.707% |
| Anew Medical, Inc. | -1.3 Million USD | -7878.844% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -739.469% |
| Lipocine Inc. | -16.32 Million USD | -535.877% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | -55.68% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | -39.687% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -172.183% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -166.038% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -367.89% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 80.958% |
| Ocugen, Inc. | -64.82 Million USD | -60.106% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | -12.123% |
| Q32 Bio Inc. | -86.5 Million USD | -19.988% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -513.174% |
| Alumis Inc. Common Stock | -156.89 Million USD | 33.844% |
| Equillium, Inc. | -12.13 Million USD | -755.1% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -77.507% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -1213.266% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -450.3% |
| Dominari Holdings Inc. | -22.44 Million USD | -362.531% |
| Edesa Biotech, Inc. | -8.19 Million USD | -1167.28% |
| vTv Therapeutics Inc. | -25.41 Million USD | -308.437% |
| Bio-Techne Corporation | 326.66 Million USD | 131.773% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 73.032% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 147.965% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 20.835% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -177.289% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 31.31% |
| Nkarta, Inc. | -120.48 Million USD | 13.852% |
| BioCardia, Inc. | -11.56 Million USD | -797.855% |
| Iterum Therapeutics plc | -34.58 Million USD | -200.15% |